This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tilly, H. Articles by Coiffier, B. Search for Related Content PubMed PubMed Citation Articles by Tilly, H. Articles by Coiffier, B.

Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study

From the Centre Henri Becquerel, Rouen; Hôpital Saint-Louis and Hôpital Laënnec, Paris; Centre Hospitalier Régional, Vandoeuvre les Nancy; Centre Hospitalier Régional, Lille; Hôpital Edouard Herriot and Centre Léon Bérard, Lyon; Centre Hospitalier Purpan, Toulouse; Hôpital Hautepierre, Strasbourg; Centre Hospitalier Universitaire, Limoges; Centre Hospitalier Lyon-Sud, Pierre Bénite, France; and Clinique Universitaire de Mont Godinne, Yvoir, Belgium.

Address reprint requests to Hervé Tilly, MD, Centre Henri Becquerel, Rue d’Amiens, 76038 Rouen, France; email herve.tilly{at}rouen fnclcc.fr.

PURPOSE: To compare a short intensified regimen followed by sequential consolidation therapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone [ACVBP]) to the standard regimen of methotrexate, bleomycin, cyclophosphamide, and etoposide (m-BACOD) in patients with low-risk aggressive lymphoma.

PATIENTS AND METHODS: A total of 752 patients with intermediate- or high-grade lymphoma and no adverse prognostic factors (Eastern Cooperative Oncology Group performance status of 2 to 4, two extranodal sites of disease, tumor burden 10 cm in largest dimension, bone marrow or CNS involvement, Burkitt’s or lymphoblastic subtypes) were registered. Of 673 eligible patients, 332 received ACVBP and 341 received m-BACOD.

RESULTS: The complete remission rate was identical (86%) in the two groups. With a median follow-up duration of 7 years, the 5-year failure-free survival (FFS) rate was 65% in the ACVBP group and 61% in the m-BACOD group (P = .16). The 5-year overall survival rate was 75% in the ACVBP group and 73% in the m-BACOD group (P = .47). ACVBP was responsible for more severe and life-threatening infections (P < .01), but m-BACOD caused more pulmonary toxicity (P < .001). The number of treatment-related deaths did not differ between the two regimens. A multivariate analysis indicated that ACVBP was associated with a longer FFS in patients with two or three risk factors of the International Prognostic Index.

CONCLUSION: In this population of patients with low-risk aggressive lymphoma, toxicities of the regimens are different, but the rates of response and survival are identical. The survival advantage of ACVBP over standard regimen in patients with advanced disease is suggested by this analysis but remains to be assessed in prospective studies specifically designed for this purpose.

This article has been cited by other articles:

				N. Mourad, N. Mounier, J. Briere, E. Raffoux, A. Delmer, A. Feller, C. J. L. M. Meijer, J.-F. Emile, R. Bouabdallah, A. Bosly, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, May 1, 2008; 111(9): 4463 - 4470. [Abstract] [Full Text] [PDF]

				L. Trumper, C. Zwick, M. Ziepert, K. Hohloch, R. Schmits, M. Mohren, R. Liersch, M. Bentz, U. Graeven, U. Wruck, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens Ann. Onc., March 1, 2008; 19(3): 538 - 544. [Abstract] [Full Text] [PDF]

				C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF]

				J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood, December 15, 2006; 108(13): 4163 - 4169. [Abstract] [Full Text] [PDF]

				H. Ghesquieres Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy Ann. Onc., August 1, 2005; 16(8): 1399 - 1399. [Full Text] [PDF]

				F. Reyes, E. Lepage, G. Ganem, T. J. Molina, P. Brice, B. Coiffier, P. Morel, C. Ferme, A. Bosly, P. Lederlin, et al. ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma N. Engl. J. Med., March 24, 2005; 352(12): 1197 - 1205. [Abstract] [Full Text] [PDF]

				N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., December 1, 2004; 15(12): 1790 - 1797. [Abstract] [Full Text] [PDF]

				M. Pfreundschuh, L. Trumper, M. Kloess, R. Schmits, A. C. Feller, C. Rudolph, M. Reiser, D. K. Hossfeld, B. Metzner, D. Hasenclever, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood, August 1, 2004; 104(3): 626 - 633. [Abstract] [Full Text] [PDF]

				M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients Blood, February 15, 2004; 103(4): 1222 - 1228. [Abstract] [Full Text] [PDF]

				H. Tilly, E. Lepage, B. Coiffier, M. Blanc, R. Herbrecht, A. Bosly, M. Attal, G. Fillet, C. Guettier, T. J. Molina, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Blood, December 15, 2003; 102(13): 4284 - 4289. [Abstract] [Full Text] [PDF]

				B. Coiffier, N. Mounier, S. Bologna, C. Ferme, H. Tilly, A. Sonet, B. Christian, O. Casasnovas, E. Jourdan, K. Belhadj, et al. Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study J. Clin. Oncol., December 1, 2003; 21(23): 4402 - 4406. [Abstract] [Full Text] [PDF]

				B. Coiffier Increasing Chemotherapy Intensity in Aggressive Lymphomas: A Renewal? J. Clin. Oncol., July 1, 2003; 21(13): 2457 - 2459. [Full Text] [PDF]

				N. Mounier, J. Briere, C. Gisselbrecht, J.-F. Emile, P. Lederlin, C. Sebban, F. Berger, A. Bosly, P. Morel, H. Tilly, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood, June 1, 2003; 101(11): 4279 - 4284. [Abstract] [Full Text] [PDF]

				R. Bouabdallah, N. Mounier, C. Guettier, T. Molina, V. Ribrag, C. Thieblemont, A. Sonet, A. Delmer, K. Belhadj, P. Gaulard, et al. T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis J. Clin. Oncol., April 1, 2003; 21(7): 1271 - 1277. [Abstract] [Full Text] [PDF]

				M. Balzarotti, M. Spina, B. Sarina, M. Magagnoli, L. Castagna, I. Milan, C. Ripa, F. Latteri, D. Bernardi, A. Bertuzzi, et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide Ann. Onc., September 1, 2002; 13(9): 1341 - 1346. [Abstract] [Full Text] [PDF]

				C. Gisselbrecht, E. Lepage, T. Molina, B. Quesnel, G. Fillet, P. Lederlin, B. Coiffier, H. Tilly, J. Gabarre, F. Guilmin, et al. Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma J. Clin. Oncol., May 15, 2002; 20(10): 2472 - 2479. [Abstract] [Full Text] [PDF]

				C. Adida, C. Haioun, P. Gaulard, E. Lepage, P. Morel, J. Briere, H. Dombret, F. Reyes, J. Diebold, C. Gisselbrecht, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood, September 1, 2000; 96(5): 1921 - 1925. [Abstract] [Full Text] [PDF]